Hexobarbital sodium cas no:50-09-9

NameHexobarbital sodium
CAS50-09-9
SynonymsHexobarbital sodium [NF XII];1,5-Dimethyl-5-cyclohexenyl-1'-barbituric acid, sodium salt;5-(1-Cyclohexen-1-yl)-1,5-dimethyl-2,4,6(1H,3H,5H)-pyrimidinetrione monosodium salt;5-(1-Cyclohexen-1-yl)-1,5-dimethylbarbituric acid sodium salt;Cyclohexenylmethyl-N-methyl barbituric acid sodium salt;Cyclonal sodium;Dorico soluble;Enhexymal NFN;Evipal Sodium;Evipan sodium;Hexanastab;Hexenal sodium;Hexobarbital sodium;Hexobarbital soluble;Hexobarbitone sodium;Methexenyl sodium;NSC 255103;Narcosan soluble;Noctivane;Novopan;Privenal;Sleepwell;Sodium 5-(1-cyclohexen-1-yl)-1,5-dimethylbarbiturate;Sodium 5-(1-cyclohexenyl)-1,5-dimethylbarbiturate;Sodium N-methyl cyclohexenylmethybarbiturate;Sodium evipal;Sodium evipan;Sodium hexabarbital;Sodium hexobarbital;Sodium hexobarbitone;Sodium methylhexabital;Sodium methylhexabitol;Sombulex;Toleran;UNII-I788X867K7;2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-, sodium salt;2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-, sodium salt (9CI);Barbituric acid, 5-(1-cyclohexen-1-yl)-1,5-dimethyl-, sodium salt;5-(cyclohex-1-en-1-yl)-1,5-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione;sodium 5-(cyclohex-1-en-1-yl)-1,5-dimethyl-4,6-dioxo-1,4,5,6-tetrahydropyrimidin-2-olate
EINECS(EC#)200-009-1
Molecular FormulaC₁₂H₁₅N₂O₃•Na
Molecular Weight258.28

Safety

Poison by intraperitoneal, parenteral, and intravenous routes. Moderately toxic by ingestion and subcutaneous routes. Used intravenously as a general anesthetic. When Evipal sodium (CAS NO.50-09-9) is heated to decomposition ,it emits toxic fumes of NO_x and Na₂O. See also EVIPAL and BARBITURATES.

RIDADR: 3249
HazardClass: 6.1(b)
PackingGroup: III

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LDLo	intravenous	85mg/kg (85mg/kg)	BEHAVIORAL: GENERAL ANESTHETIC	Journal of Pharmacology and Experimental Therapeutics. Vol. 60, Pg. 125, 1937.
dog	LDLo	subcutaneous	107mg/kg (107mg/kg)	BEHAVIORAL: SLEEP	Journal of Pharmacology and Experimental Therapeutics. Vol. 60, Pg. 323, 1937.
frog	LDLo	parenteral	30mg/kg (30mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 50, Pg. 347, 1934.
guinea pig	LDLo	intraperitoneal	100mg/kg (100mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: ATAXIA BEHAVIORAL: COMA	Journal of Pharmacology and Experimental Therapeutics. Vol. 50, Pg. 347, 1934.
mouse	LD50	intraperitoneal	240mg/kg (240mg/kg)		Acta Biologica et Medica Germanica. Vol. 6, Pg. 407, 1961.
mouse	LD50	intravenous	165mg/kg (165mg/kg)		Toxicology and Applied Pharmacology. Vol. 23, Pg. 537, 1972.
mouse	LD50	oral	1325mg/kg (1325mg/kg)		Toxicology and Applied Pharmacology. Vol. 27, Pg. 70, 1974.
mouse	LD50	subcutaneous	410mg/kg (410mg/kg)		Toxicology and Applied Pharmacology. Vol. 27, Pg. 70, 1974.
rabbit	LD50	intravenous	72mg/kg (72mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 87, Pg. 265, 1946.
rabbit	LDLo	intraperitoneal	150mg/kg (150mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 54, Pg. 77, 1935.
rat	LCLo	inhalation	2000ppm/4H (2000ppm)		AMA Archives of Industrial Hygiene and Occupational Medicine. Vol. 10, Pg. 61, 1954.
rat	LD50	intraperitoneal	375mg/kg (375mg/kg)		Journal of Pharmacy and Pharmacology. Vol. 21, Pg. 109, 1969.
rat	LD50	oral	1gm/kg (1000mg/kg)		Archives of Toxicology. Vol. 54, Pg. 275, 1983.
rat	LDLo	subcutaneous	363mg/kg (363mg/kg)	BEHAVIORAL: SLEEP	Journal of Pharmacology and Experimental Therapeutics. Vol. 60, Pg. 323, 1937.